StockData
Inhibrx Biosciences, Inc. logo

Inhibrx Biosciences, Inc. (INBX) company profile

INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$74.18−3.48 (-4.48%)

Close on Nov 17, 2026Market cap $1.09BP/E –Yield –

About Inhibrx Biosciences

Biological Products, (No Diagnostic Substances), SIC 2836

Inhibrx operates as a clinical-stage biopharmaceutical company focused on discovering and developing novel biologic therapeutic candidates. The company engineers these candidates using proprietary modular protein engineering platforms and single domain antibody technologies designed to address challenging biological targets. Its active clinical pipeline centers on two oncology programs: ozekibart (INBRX-109), a tetravalent DR5 agonist evaluated for chondrosarcoma, Ewing sarcoma, and colorectal adenocarcinoma, and INBRX-106, a hexavalent OX40 agonist investigated for solid tumors such as non-small cell lung cancer and head and neck squamous cell carcinoma. Because its therapeutic candidates are currently in clinical development, the company has no approved commercial products and does not yet serve end customers.

The company conducts clinical research internationally, including a global clinical trial conducted across 68 sites worldwide. Its patent estate spans the United States along with international jurisdictions including Europe, Australia, Canada, China, and Japan. The provided text does not mention the location of the company's headquarters.

Summary of the business section of Inhibrx Biosciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Inhibrx Biosciences, Inc.
Headquarters
La Jolla, CA
Address
11025 N. Torrey Pines Road, Suite 140 92037
Phone
(858) 795-4220
Employees
110, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
BDO USA, P.C., San Diego, California

Stock & identifiers

Ticker
INBX
Former tickers
INXB until Jun 17, 2024
Exchange
Nasdaq
IPO date
May 29, 2024
Shares outstanding
15M, Aug 7, 2026
Public float
$174.60M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Stock splits
1-for-4 reverse, Aug 13, 2024
SEC CIK
2007919
CUSIP
457CVR017
ISIN
US457CVR0178
FIGI
BBG01MS5Q9G3
Share class FIGI
BBG01MS5QB96
EIN
99-0613523

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Mark LappeChief Executive Officer, Director970,453
David MatlyPresident–
Kelly DeckChief Financial Officer–
Jon Faiz KayyemDirector1,074,046
Douglas ForsythDirector227,064
Kristiina Vuori MDDirector20,443
Kimberly ManhardDirector7,500

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsIncentive payOtherTotalvs. prior year
Mark P. Lappe
Chief Executive Officer and Chairman of the Board of Directors
$695.25K$1.70M–$479.72K$17.50K$2.89M-38%
Kelly D. Deck
Chief Financial Officer
$493.49K–$157.29K$255.43K$17.50K$923.70K-78%
David J. Matly
President
$589.17K–$524.29K$304.99K$17.50K$1.44M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 110 employees, 109 of whom were full-time, 84 of whom were engaged in research and development activity, and 51 of which hold advanced degrees, including but not limited to Ph.D., M.D., PharmD, J.D., MBA, and other master’s degrees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?